Monopar Therapeutics (MNPR) acting CMO plans 1-share sale

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) insider Patrice Rioux, Acting Chief Medical Officer, filed a Rule 144 notice to sell 1 share of Monopar common stock. The planned sale, through Morgan Stanley Smith Barney LLC, is tied to an exercise of stock options for cash on or about August 26, 2026, with Form 144 indicating 6,712,172 shares outstanding and an aggregate market value reference of $110.82 for the shares to be sold.

Key Figures

Number of shares to be sold: 1 share Aggregate market value: $110.82 Shares outstanding: 6,712,172 shares +1 more

4 metrics

Number of shares to be sold 1 share Planned sale of Monopar common stock under Rule 144

Aggregate market value $110.82 Value associated with the shares to be sold under the Form 144 notice

Shares outstanding 6,712,172 shares Monopar common stock reported outstanding in the Form 144

Approximate sale date 08/26/2026 Approximate date of sale for the shares covered by the notice

Key Terms

Rule 144, Exercise of Stock Options, Aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 08/26/2026 | Exercise of Stock Options | Issuer"

Aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 | 1 | 110.82 | 6712172"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does Monopar Therapeutics (MNPR) disclose in this Form 144 filing?

The filing shows Acting Chief Medical Officer Patrice Rioux plans to sell 1 share of Monopar common stock under Rule 144, following an exercise of stock options for cash, with an indicated aggregate market value of $110.82 and an approximate sale date of August 26, 2026.

How many Monopar Therapeutics (MNPR) shares are planned to be sold under this notice?

The notice covers the planned sale of 1 share of Monopar Therapeutics common stock, as reported in the Form 144 securities information section.

What is the indicated market value for the Monopar (MNPR) shares in this Form 144?

The Form 144 lists an aggregate market value of $110.82 for the Monopar common shares covered by this notice.

When is the sale of Monopar Therapeutics (MNPR) shares expected under this Form 144?

The Form 144 indicates an approximate sale date of August 26, 2026 for the Monopar common shares to be sold under Rule 144.

How many Monopar Therapeutics (MNPR) shares are reported as outstanding?

The Form 144 reports 6,712,172 shares of Monopar Therapeutics common stock outstanding, providing context for the size of the planned 1‑share sale.

What is the source of the Monopar (MNPR) shares being sold in this Form 144?

The shares are reported as acquired through an exercise of stock options from the issuer, with the nature of payment indicated as cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:20 PM Accepted by SEC EDGAR 08/26/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001241033
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MONOPAR THERAPEUTICS INC.
SEC File Number	001-39070
Address of Issuer	1000 Skokie Blvd., Suite 350 Wilmette ILLINOIS 60091
Phone	847-388-0349
Name of Person for Whose Account the Securities are To Be Sold	PATRICE RIOUX
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Acting Chief Medical Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1	110.82	6712172	08/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2026	Exercise of Stock Options	Issuer			1	08/26/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ PATRICE RIOUX
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)